REGN - Regeneron Pharmaceuticals, Inc.
IEX Last Trade
729.15
-2.400 -0.329%
Share volume: 22,012
Last Updated: Tue 07 Jan 2025 08:30:01 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.90%
PREVIOUS CLOSE
CHG
CHG%
$731.55
-2.40
-0.33%
View ratios
Fiscal Date | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
---|---|---|---|---|---|---|---|
Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
Report Date | 2023-05-04 | 2023-08-03 | 2023-11-02 | 2024-02-05 | 2024-05-02 | 2024-08-01 | |
Total revenue | 3.162 B | 3.158 B | 3.363 B | 3.434 B | 3.145 B | 3.547 B | |
Cost of revenue | 208.400 M | 192.400 M | 224.500 M | 306.800 M | 240.400 M | 257.800 M | |
Gross profit | 2.954 B | 2.966 B | 3.138 B | 3.128 B | 2.905 B | 3.289 B | |
0.41% | 5.82% | -0.34% | -7.13% | 13.24% | |||
Operating expenses | 1.702 B | 1.737 B | 1.716 B | 1.915 B | 1.937 B | 1.959 B | |
Selling general and admin | 601.100 M | 652.000 M | 640.500 M | 737.700 M | 689.000 M | 758.800 M | |
Research and development | 1.101 B | 1.085 B | 1.075 B | 1.177 B | 1.248 B | 1.200 B | |
Total expenses | 2.160 B | 2.142 B | 2.152 B | 2.432 B | 2.371 B | 2.439 B | |
-0.81% | 0.47% | 13.00% | -2.50% | 2.86% | |||
Operating income | 1.002 B | 1.016 B | 1.211 B | 1.002 B | 773.800 M | 1.108 B | |
Ebit | 1.002 B | 1.016 B | 1.211 B | 1.002 B | 773.800 M | 1.108 B | |
Pretax income | 858.000 M | 1.083 B | 1.111 B | 1.148 B | 700.700 M | 1.628 B | |
26.21% | 2.58% | 3.31% | -38.94% | 132.35% | |||
Income tax | 40.200 M | 114.500 M | 103.000 M | -12.000 M | -21.300 M | 195.800 M | |
Net income basic | 817.800 M | 968.400 M | 1.008 B | 1.160 B | 722.000 M | 1.432 B | |
18.42% | 4.07% | 15.06% | -37.74% | 98.38% | |||
Net income | 817.800 M | 968.400 M | 1.008 B | 1.160 B | 722.000 M | 1.432 B | |
18.42% | 4.07% | 15.06% | -37.74% | 98.38% |